# Protective Effect of Probacine Against Negative Gut Metabolism and Organ Dysfunction After Cardiovascular Surgery (PANDA IV)

> **NCT04444362** · NA · ENROLLING_BY_INVITATION · sponsor: **Nanjing Medical University** · enrollment: 500 (estimated)

## Conditions studied

- Cardiovascular Disease
- Cardiopulmonary Bypass

## Interventions

- **DRUG:** Intestinal Microbiota Transplant (IMT) Capsules

## Key facts

- **NCT ID:** NCT04444362
- **Lead sponsor:** Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2025-01-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2026-01-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04444362

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04444362, "Protective Effect of Probacine Against Negative Gut Metabolism and Organ Dysfunction After Cardiovascular Surgery (PANDA IV)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04444362. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*